Vanguard reports 6.75M SRPT shares (6.43%)
Sarepta Therapeutics: Vanguard Portfolio Management reports ownership of 6,751,168 shares of Common Stock, representing 6.43% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Sarepta Therapeutics: Vanguard Portfolio Management reports ownership of 6,751,168 shares of Common Stock, representing 6.43% of the class. The filing states Vanguard has sole dispositive power over 6,751,168 shares and sole voting power over 110,476 shares. The statement is signed by Ashley Grim on 04/29/2026.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
sole dispositive power regulatory
investment companies registered under the Investment Company Act regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What voting and dispositive powers does Vanguard report for SRPT?
When was the Schedule 13G for SRPT signed and by whom?
Does the Vanguard filing identify other persons with more than 5% ownership of SRPT?
What does 'beneficially owned' mean in this Schedule 13G for SRPT?
AI-generated analysis. How Rhea-AI works. Not financial advice.